Immunomedics (IMMU) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Barclays Starts Immunomedics (IMMU) at Overweight
May 4, 2020 5:31 PM EDTBarclays analyst Peter Lawson initiates coverage on Immunomedics (NASDAQ: IMMU) with a Overweight rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Immunomedics click here. For more ratings news on Immunomedics click here.
Shares of Immunomedics closed at $30.38 yesterday.
... MoreImmunomedics (IMMU) Announces Commercial Availability of TRODELVY in United States
May 4, 2020 8:09 AM EDTImmunomedics, Inc., (NASDAQ: IMMU), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today... More
